Scinai Immunotherapeutics (SCNI) EBIT (2014 - 2024)

Scinai Immunotherapeutics has disclosed EBIT across 11 years of filings, most recently posting -$2.3 million for Q4 2024.

• EBIT for Q4 2024 came in at -$2.3 million, down 24.14% year-over-year; the trailing twelve-month figure through Dec 2024 was -$8.6 million (down 565.41% YoY), and the FY2025 annual result was -$9.7 million, down 12.82% from the prior year.
• EBIT came in at -$2.3 million for Q4 2024 at Scinai Immunotherapeutics, up from -$2.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $55.6 million in Q3 2020 to a low of -$20.0 million in Q1 2020.
• The 5-year median for EBIT is -$2.1 million (2023), against an average of -$304315.8.
• Across the five-year window, EBIT surged 393.84% in 2020 and sank 326.71% in 2024, its largest moves.
• Scinai Immunotherapeutics' EBIT stood at -$12.1 million in 2020, then soared by 207.34% to $13.0 million in 2021, then sank by 246.66% to -$19.1 million in 2022, then surged by 90.46% to -$1.8 million in 2023, then retreated by 24.14% to -$2.3 million in 2024.
• The last three EBIT figures came in at -$2.3 million (Q4 2024), -$2.4 million (Q3 2024), and -$5.9 million (Q2 2024), per Business Quant data.